Amphastar Pharmaceuticals, Inc. (AMPH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 350 | 438 | 499 | 644 | 732 | 720 | 730 | 748 |
| Operating profit | $m | 140 | 114 | ||||||
| Net profit | $m | 1 | 62 | 91 | 138 | 160 | 98 | 79 | 135 |
| EPS reported | $ | 2.03 | 1.69 | ||||||
| Operating cashflow per share | $ | 3.34 | 4.23 | ||||||
| Capex per share | $ | 0.75 | 0.73 | ||||||
| FCF per share | $ | 2.59 | 3.50 | ||||||
| Free cash flow | $m | 121 | 153 | ||||||
| Net debt | $m | 327 | 322 | ||||||
| Book value equity | $m | 789 | 768 | ||||||
| Book value per share | $ | 16.36 | 17.37 | ||||||
| Number of shares | m | 48.22 | 44.23 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 13.19 | 16.21 | ||||||
| P/B LTM | x | 1.59 | 1.63 | ||||||
| P/S LTM | x | 1.74 | 1.71 | ||||||
| P/FCF LTM | x | 10.33 | 8.19 | ||||||
| EV/EBITDA LTM | x | 8.18 | 9.94 | ||||||
| EV/Sales LTM | x | 2.41 | 2.04 | ||||||
| Earnings Yield LTM | % | +7.58% | +6.17% | ||||||
| FCF Yield | % | +9.68% | +12.21% | ||||||
| Quality | |||||||||
| ROE | % | +12.44% | +10.11% | ||||||
| ROIC | % | +7.52% | +5.90% | ||||||
| Operating margin | % | +19.50% | +15.66% | ||||||
| Gross margin | % | +49.46% | +47.68% | ||||||
| FCF/Sales | % | +16.84% | +20.94% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -33.66% | -44.77% | ||||||
| Sales Growth YoY | % | -1.65% | -0.27% | ||||||
| Net Income Growth YoY | % | -38.51% | -50.76% | ||||||
| FCF Growth | % | -29.66% | -11.29% | ||||||
| Operating Profit Growth | % | -31.65% | -44.36% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.18 | 0.22 | ||||||
| Net Debt/EBITDA | x | 2.29 | 2.66 | ||||||
| EBIT/Net interest | x | 5.51 | 4.37 | ||||||
| Net debt/market cap | % | +48.75% | +59.88% | ||||||
| Net debt/Equity | x | 0.42 | 0.42 | ||||||
| Gross debt/equity | x | 0.83 | 0.90 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Amphastar Pharmaceuticals, Inc. (AMPH)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free